Terms: = Liver cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG
399 results:
1. Medicaid expansion and palliative care for advanced-stage liver cancer.
Lima HA; Mavani P; Munir MM; Endo Y; Woldesenbet S; Khan MMM; Rawicz-Pruszyński K; Waqar U; Katayama E; Resende V; Khalil M; Pawlik TM
J Gastrointest Surg; 2024 Apr; 28(4):434-441. PubMed ID: 38583893
[TBL] [Abstract] [Full Text] [Related]
2. Sarcomatoid hepatocellular carcinoma: A case report and review of the literature.
Hu C; Zhao M; Wei Q; Chen Z; Zhao B
Medicine (Baltimore); 2024 Mar; 103(13):e37641. PubMed ID: 38552058
[TBL] [Abstract] [Full Text] [Related]
3. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
4. [Clinicopathological features of intravascular large B-cell lymphoma and collision tumors of five cases].
Liu J; Liu GZ; Xia L; Wang HY; Zhang XF; Liu H
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):22-28. PubMed ID: 38178742
[No Abstract] [Full Text] [Related]
5. Decoding the rhabdoid riddle in liver: A rare case of primary hepatic malignant rhabdoid tumor with a comprehensive literature review.
Kerkar A; Gupta P; Azeez A; Bhatia A; Gupta N; Bansal D
Diagn Cytopathol; 2024 Mar; 52(3):E69-E75. PubMed ID: 38059387
[TBL] [Abstract] [Full Text] [Related]
6. GLI1-Altered Mesenchymal Tumors With ACTB or PTCH1 Fusion: A Molecular and Clinicopathologic Analysis.
Kerr DA; Cloutier JM; Margolis M; Mata DA; Rodrigues Simoes NJ; Faquin WC; Dias-Santagata D; Chopra S; Charville GW; Wangsiricharoen S; Lazar AJ; Wang WL; Rosenberg AE; Tse JY
Mod Pathol; 2024 Feb; 37(2):100386. PubMed ID: 37992966
[TBL] [Abstract] [Full Text] [Related]
7. Small Intestinal Adenocarcinoma Arising at the Anastomotic Site after Kasai Operation for Biliary Atresia: A Case Report and Literature Review.
Ishikawa Y; Saito R; Murakami K; Fujio A; Miyazawa K; Sasaki K; Matsumura M; Mitsugashira H; Degawa K; Kobayashi Y; Muto R; Tokodai K; Furukawa T; Unno M; Kamei T
Tohoku J Exp Med; 2023 Dec; 261(4):267-272. PubMed ID: 37766552
[TBL] [Abstract] [Full Text] [Related]
8. Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
Mariani P; Torossian N; van Laere S; Vermeulen P; de Koning L; Roman-Roman S; Lantz O; Rodrigues M; Stern MH; Gardrat S; Lesage L; Champenois G; Nicolas A; Matet A; Cassoux N; Servois V; Romano E; Piperno-Neumann S; Lugassy C; Barnhill R
Br J Cancer; 2023 Sep; 129(5):772-781. PubMed ID: 37443346
[TBL] [Abstract] [Full Text] [Related]
9. Development of Engineered CAR T Cells Targeting Tumor-Associated Glycoforms of muc1 for the Treatment of Intrahepatic Cholangiocarcinoma.
Mao L; Su S; Li J; Yu S; Gong Y; Chen C; Hu Z; Huang X
J Immunother; 2023 Apr; 46(3):89-95. PubMed ID: 36883998
[TBL] [Abstract] [Full Text] [Related]
10. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
Krimmel L; Quante M; Bengsch B
Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
[TBL] [Abstract] [Full Text] [Related]
11. Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patients.
Donnette M; Osanno L; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Costello R; Caroline S; Ouafik L'; Ciccolini J; Fanciullino R
Cancer Chemother Pharmacol; 2023 Mar; 91(3):231-238. PubMed ID: 36859512
[TBL] [Abstract] [Full Text] [Related]
12. The multifaceted role of muc1 in tumor therapy resistance.
Jin W; Zhang M; Dong C; Huang L; Luo Q
Clin Exp Med; 2023 Sep; 23(5):1441-1474. PubMed ID: 36564679
[TBL] [Abstract] [Full Text] [Related]
13. Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update.
Ferenci P; Reiberger T; Jachs M
Cells; 2022 Nov; 11(22):. PubMed ID: 36428959
[TBL] [Abstract] [Full Text] [Related]
14. Circulating tumor cells as a prognostic biomarker in patients with hepatocellular carcinoma.
Prasoppokakorn T; Buntho A; Ingrungruanglert P; Tiyarattanachai T; Jaihan T; Kulkraisri K; Ariyaskul D; Phathong C; Israsena N; Rerknimitr R; Treeprasertsuk S; Chaiteerakij R
Sci Rep; 2022 Nov; 12(1):18686. PubMed ID: 36333384
[TBL] [Abstract] [Full Text] [Related]
15. Genetic alterations shaping tumor response to anti-EGFR therapies.
Vaquero J; Pavy A; Gonzalez-Sanchez E; Meredith M; Arbelaiz A; Fouassier L
Drug Resist Updat; 2022 Sep; 64():100863. PubMed ID: 36063655
[TBL] [Abstract] [Full Text] [Related]
16. BTLA
Diskin B; Adam S; Soto GS; Liria M; Aykut B; Sundberg B; Li E; Leinwand J; Chen R; Kim M; Salas RD; Cassini MF; Buttar C; Wang W; Farooq MS; Shadaloey SAA; Werba G; Fnu A; Yang F; Hirsch C; Glinski J; Panjwani A; Weitzner Y; Cohen D; Asghar U; Miller G
Oncogene; 2022 Sep; 41(38):4349-4360. PubMed ID: 35948648
[TBL] [Abstract] [Full Text] [Related]
17. "A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring".
Soledad Poetto A; Posocco B; Zanchetta M; Gagno S; Orleni M; Canil G; Alberti M; Puglisi F; Toffoli G
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Sep; 1207():123403. PubMed ID: 35940043
[TBL] [Abstract] [Full Text] [Related]
18. RUNX3-Regulated GALNT6 Promotes the Migration and Invasion of Hepatocellular Carcinoma Cells by Mediating O-Glycosylation of muc1.
Gao F; Zheng G
Dis Markers; 2022; 2022():2959846. PubMed ID: 35909886
[TBL] [Abstract] [Full Text] [Related]
19. LINC02535/miR-30a-5p/GALNT3 axis contributes to lung adenocarcinoma progression via the NF- κ B signaling pathway.
Li Y; Zhao J; Zhang W; Wang A; Jiao M; Cai X; Zhu J; Liu Z; Huang JA
Cell Cycle; 2022 Dec; 21(23):2455-2470. PubMed ID: 35852407
[TBL] [Abstract] [Full Text] [Related]
20. Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data.
Fishman P
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744805
[TBL] [Abstract] [Full Text] [Related]
[Next]
